Yixin Yu, Xianguang Zhao, Xudong Xu, Chenwen Cai, Xuemei Tang, Qingyun Zhang, Liang Zhong, Fusheng Zhou, Dongqin Yang, Zhiling Zhu
Inflammatory bowel disease (IBD) affects millions of individuals worldwide annually. Enteric reactive oxygen species (ROS) play critical roles in the physiology and pathology of IBD. Nanozymes hold great promise for the treatment of IBD because of their exceptional ability to regulate redox homeostasis during ROS-related inflammation. However, the rapid development of orally administered, acid-tolerant, antioxidant nanozymes for IBD therapy is challenging. Herein, a nine-tier high-throughput screening strategy was established to address the multifaceted IBD treatment demands, including intrinsic stability, radioactivity, solubility, gut microbiome toxicity, biomimetic elements, intermediate frontier molecular orbitals, reaction energy barriers, negative charges, and acid tolerance...
August 23, 2023: Advanced Materials